New strategy aims to tame dangerous immune storms after stem cell transplants
NCT ID NCT06828796
Summary
This study is testing if giving an immunosuppressant drug called tacrolimus earlier in the stem cell transplant process can safely reduce a dangerous immune overreaction called Cytokine Release Syndrome (CRS). It involves 20 patients with blood cancers who are receiving a transplant from a partially matched family donor. The main goal is to see if this timing change lowers the risk and severity of CRS in the first days after transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC DISEASE AND DISORDERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Northside Hospital
RECRUITINGAtlanta, Georgia, 30342, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.